Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies

Eun Sung Jeong, Kyo Won Lee, Sang Jin Kim, Hee Jin Yoo, Kyung A. Kim, Jae Berm Park

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: Graft survival rate of kidney transplantation recipients improves after induction therapy. However, there is no conclusive evidence on which regimen is superior for deceased donor kidney transplantation (DDKT). This study aims at discussing effective induction therapy in DDKT. Methods: Between 2003 and 2016, 395 DDKT recipients were divided into three groups following induction therapy. Recipients of the basiliximab group (n=184) received basiliximab (20 mg/kg) on days 0 and 4. Recipients of the low-dose rabbit anti-thymocyte globulin (rATG) group (n=113) received rATG (1.5 mg/kg) on days 0, 1, and 2, while those of the high-dose rATG group (n=98) received it for more than 4 days. We retrospectively reviewed and analyzed the clinical outcomes and adverse effects of induction therapy. Results: Compared to other groups, the low-dose rATG group donors were older (P<0.001); rATG group donors had higher serum creatinine levels (P<0.001), and the basiliximab group showed a lower delayed graft function rate (P=0.004). In graft failure, the low-dose rATG group did not differ significantly from the basiliximab group (P=0.080), but was significantly different from the high-dose rATG group (P=0.004). Conclusions: The low-dose rATG group had the best graft survival rate, although it had older donors and higher serum creatinine levels. Therefore, low-dose rATG may be considered an effective induction therapy in DDKT.

Original languageEnglish
Pages (from-to)118-127
Number of pages10
JournalKorean Journal of Transplantation
Volume33
Issue number4
DOIs
StatePublished - 31 Dec 2019

Keywords

  • Graft rejection
  • Immunosuppressive agent
  • Kidney transplantation

Fingerprint

Dive into the research topics of 'Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies'. Together they form a unique fingerprint.

Cite this